Can an immunotherapy drug keep liver cancer at bay after surgery?

NCT ID NCT03859128

Ongoing Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receive toripalimab and half a placebo, and the study will compare how long they remain free of cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to: If successful, this could offer a new way to delay or prevent liver cancer from coming back after surgery, potentially improving long-term outcomes.
What could go wrong: This is a mid-to-late-stage trial, but results are not guaranteed. The drug may not improve recurrence-free survival, and immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Zhongshan Hospital,Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.